David Foehr Sells 781 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 781 shares of the stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $19.98, for a total transaction of $15,604.38. Following the completion of the sale, the vice president owned 17,550 shares in the company, valued at $350,649. The trade was a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Foehr also recently made the following trade(s):

• On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $11,260.51.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Stock Up 2.3%

CeriBell stock opened at $19.39 on Friday. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $25.37. The stock has a market capitalization of $719.29 million, a PE ratio of -13.19 and a beta of 1.03. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 12.25. The business has a 50 day simple moving average of $21.17 and a 200-day simple moving average of $16.21.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Trending Headlines about CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 results beat estimates — CeriBell reported Q4 EPS of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expected, a fundamental beat that supports the share uptick. Zacks: Q4 Loss, Beats Revenue
• Positive Sentiment: Management set FY‑2026 revenue guidance (~$111M–$115M) roughly in line with consensus, giving investors a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call emphasized accelerating revenue and market expansion — management commentary reinforced the beat/guidance story and helped push sentiment positive. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data for February appears unreliable (reported as zero/NaN) and provides no actionable signal at this time.
• Negative Sentiment: Clustered insider selling — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold modest amounts at ~$19.8–$20.0, trimming positions by fractions of a percent; sales are small relative to total holdings but can create short‑term concern. InsiderTrades: Insider Sales

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CeriBell in the 3rd quarter worth about $33,000. CWM LLC grew its holdings in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CBLL. JPMorgan Chase & Co. decreased their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Canaccord Genuity Group raised their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 target price on shares of CeriBell in a report on Wednesday, January 28th. Finally, TD Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.